FOR IMMEDIATE RELEASE
JUNE 6, 2019 ANN ARBOR, MI
Fusion Genes Found to be an Emerging Target in Cancer Diagnostics and Drug Development
Genomenon Releases New Report on Fusion Genes of Clinical Significance in 2019
Genomenon® has released a research report detailing fusion genes of clinical significance found as of April 2019. Fusion genes have long been known to play an important role in the development of cancer. Identifying and documenting each newly discovered fusion is crucial in both patient diagnosis and the development of precision medicines (specifically, targeted therapeutics). The report was compiled using research data found in the Mastermind® Genomic Search Engine.
The Genomenon team used Mastermind to compile a comprehensive knowledgebase of literature describing gene fusions in order to analyze the data and relate the findings in the report. This is the most exhaustive fusion gene knowledgebase in existence, due to the completeness of the Mastermind literature database and the way Mastermind employs Machine Learning (ML) and Artificial Intelligence (AI) to organize and present the data.
The report includes:
- Top Fusion Partners by Number of Articles
- New Fusion Genes in Cancer for 2019
The data reveals:
- Over 140 novel gene fusions were found across nearly 500,000 newly published scientific articles containing genomic content in 2018
- Eleven novel fusions involved in the genesis of multiple cancer types have been found in newly published scientific articles in 2019
- Both the number of articles describing novel (new) fusions and the number of articles describing all known fusions have experienced a relatively constant increase from 1987 to 2018, indicating a need to stay current with newly published information
The report is available here: Genomenon Research Report: Fusion Genes of Clinical Significance in 2019
This report was published in cooperation with The Journal of Precision Medicine.
The Mastermind Genomic Search Engine is an evidence-based interpretation tool which provides immediate insight into the full text of millions of genomic articles and supplemental data for every disease, gene, and variant found in the literature. Mastermind is used by hundreds of diagnostic labs around the world to accelerate genomic interpretation, and by pharmaceutical companies to provide a comprehensive genomic landscape for any disease.
Genomenon powers evidence-based genomics for faster; more comprehensive diagnosis and treatment decisions. Their flagship product, the Mastermind Genomic Search Engine provides immediate insight into the published genomic research for every disease, gene, and variant found in the literature.
Used by hundreds of diagnostic labs around the world, Mastermind accelerates genomic interpretation by providing unique insight into genomic relationships found in the full text of millions of scientific articles.
Pharmaceutical researchers license the Mastermind database for a comprehensive genomic landscape associated with any given disease – to identify and prioritize genomic biomarkers for drug discovery and clinical trial targets.